1 What Is Transfer Pricing and Why Should You Care?

The Risk You Cannot Afford to Ignore

If your pharma company operates in more than one country — and especially if you have IP, manufacturing, or R&D in different jurisdictions — transfer pricing is one of the largest financial risks on your balance sheet. Get it wrong and you face penalties of 20-75% of the adjustment, double taxation, and regulatory scrutiny that can persist for years.

This is not an abstract compliance exercise. Transfer pricing disputes have cost pharmaceutical companies hundreds of millions of dollars in additional taxes, penalties, and interest. They have consumed years of management attention, strained relationships with tax authorities in multiple jurisdictions simultaneously, and in some cases forced companies to restate financial results.

Yet many pharma CFOs — particularly at emerging and mid-size companies — treat transfer pricing as a back-office tax compliance task. It is not. Transfer pricing is a strategic financial function that sits at the intersection of tax planning, operational structure, and regulatory risk management. And in pharma, the stakes are higher than in virtually any other industry.

This guide is designed to help you understand the landscape, ask the right questions of your advisors, evaluate whether your current structure and documentation are adequate, and identify the most common pitfalls that trigger audits, adjustments, and penalties.

Transfer Pricing in Plain English

Transfer pricing is the price one part of your company charges another part for goods, services, or intellectual property. These are intercompany transactions — deals between related entities within the same multinational group.

Here are a few examples that will be familiar to any pharma CFO:

• Patent licensing. Your US parent company developed a blockbuster oncology drug. The compound is patented in the US, but your Irish manufacturing subsidiary produces the API and finished dosage form for global distribution. The royalty rate your Irish subsidiary pays the US parent for the right to use that patent is a transfer price. If the royalty is too low, the IRS will argue that profits are being shifted to Ireland. If it is too high, Irish Revenue will argue the same in reverse.
• Contract manufacturing. Your German subsidiary manufactures API for the US parent under a toll manufacturing arrangement. The price your US entity pays for that API is a transfer price. Both the IRS and the German tax authority will scrutinize whether that price reflects what an unrelated contract manufacturer would charge.
• Contract research. Your Swiss subsidiary operates a clinical development center that runs Phase II and Phase III trials for the US parent. The fee the US parent pays for those clinical services is a transfer price. The question is whether the Swiss entity is simply performing services (earning a routine return) or contributing to the creation of valuable IP (earning a share of residual profits).
• Management fees. Your US headquarters provides corporate services — legal, finance, HR, IT, regulatory affairs — to subsidiaries worldwide. The fees charged for those services are transfer prices. Tax authorities frequently challenge management fees that appear to be profit-shifting mechanisms disguised as service charges.
• Distribution margins. Your Singapore subsidiary distributes finished pharmaceutical products across Asia-Pacific. The price at which it purchases product from the Irish manufacturing entity — and the margin it earns on resale — are transfer prices.

Every one of these transactions must be priced as if the two related entities were independent companies dealing with each other at arm's length. That is the foundational principle of transfer pricing worldwide.

The Arm's Length Principle

The arm's length principle is the global standard for transfer pricing, codified in the OECD Transfer Pricing Guidelines and adopted by more than 100 countries. The principle is straightforward in concept:

Intercompany transactions must be priced at the same amount that unrelated parties would agree to in comparable circumstances.

If your Irish subsidiary licenses a drug patent from the US parent at a 5% royalty rate, but comparable unrelated licensing deals in the pharmaceutical industry involve royalties of 12-18%, tax authorities will argue that the 5% rate does not reflect arm's length pricing. They will adjust your taxable income as if the royalty had been set at the arm's length rate — and they will assess penalties on the adjustment.

The arm's length principle sounds simple. In practice, applying it to pharmaceutical transactions is anything but simple. The reason: most pharmaceutical IP is unique. There is no open market for a specific drug patent at a specific stage of development with a specific efficacy profile and competitive landscape. Finding truly "comparable" transactions between unrelated parties is one of the central challenges of pharma transfer pricing.

The Comparability Challenge in Pharma

The arm's length principle requires comparing intercompany transactions to comparable transactions between unrelated parties. In pharma, this comparability challenge is particularly acute across all transaction types:

• Drug patent licensing. Each pharmaceutical patent is unique — a specific molecule with a specific mechanism of action, specific clinical data, specific regulatory status, and a specific competitive landscape. Comparability factors include therapeutic area, mechanism novelty, development stage, patent remaining life, market size, competitive intensity, and deal structure.
• Contract R&D services. Pharma R&D involves highly qualified scientists (PhDs in medicinal chemistry, pharmacology, biostatistics), expensive equipment, regulatory complexity (GLP, GCP compliance), and long project timelines.
• Contract manufacturing. Pharmaceutical manufacturing is heavily regulated (GMP compliance, FDA/EMA inspections) and highly specialized (sterile manufacturing, biologics, controlled substances).
• Distribution. Pharma distribution involves regulatory requirements (cold chain, serialization), market access functions (formulary negotiations), and medical affairs activities not present in other industries.

When the Arm's Length Principle Breaks Down

There are situations in pharma where the arm's length principle is particularly difficult to apply:

• Unique, first-in-class compounds. No comparable uncontrolled licensing transaction exists because no one has ever licensed a comparable product.
• Integrated R&D and manufacturing. Separating the R&D return from the manufacturing return is conceptually difficult when the manufacturing process is itself a form of IP.
• Multi-entity development programs. When five entities across three countries contribute to a single drug development program over 12 years, allocating the resulting IP value is inherently complex.

Why Pharma Is a Lightning Rod for Transfer Pricing Scrutiny

Pharmaceutical and biotechnology companies attract disproportionate transfer pricing attention from tax authorities worldwide. There are six structural reasons:

1. Massive Intellectual Property Portfolios

Pharma companies hold some of the most valuable intellectual property on earth. A single drug patent can generate billions of dollars in annual revenue over its exclusivity period. The aggregate IP value in a mid-size pharma company can exceed $10 billion. Tax authorities in the US, UK, Germany, and Australia all have specialized pharma audit teams.

2. High R&D Spending with Long Development Timelines

The average cost to bring a new drug to market is estimated at $1.3 to $2.6 billion. Development timelines span 10 to 15 years from discovery through FDA or EMA approval. During that time, R&D activities may be performed by entities in multiple countries, each with a potential claim to IP value.

3. Complex Multinational Structures

A typical mid-size pharma company with $1 billion or more in revenue operates through 15 to 50 legal entities across 10 to 30 countries. Each intercompany link generates transfer prices that must be set, documented, and defended.

4. Large Intercompany Financial Flows

It is not unusual for a mid-size pharma company's intercompany flows to exceed its third-party revenue. Consider a company with $2 billion in external sales: IP royalties alone can reach $200-400 million, contract manufacturing fees $300-600 million, and management fees $30-100 million.

5. Historical Profit Allocation to Low-Tax Jurisdictions

The pharmaceutical industry pioneered many of the IP migration and profit-shifting structures now under global scrutiny. These created a pattern that tax authorities now recognize and target.

6. Tax Authorities Specifically Target Pharma

The IRS has dedicated pharmaceutical audit teams within its Large Business and International Division. HMRC has publicly discussed pharma transfer pricing in enforcement guidance. The European Commission's state aid investigations have targeted pharmaceutical company tax rulings in Ireland, the Netherlands, and Luxembourg.

The Financial Stakes

Direct Financial Exposure

• Average transfer pricing adjustment for mid-size pharma: $10 million to $50 million per audit cycle. For large pharma, adjustments of $100 million or more are not uncommon.
• Penalties: 20% of the adjustment (US standard) to 75%+ (fraud or willful neglect). If the adjustment exceeds $20 million, the US penalty increases to 40%.
• Interest on underpayments from the original due date through payment. For audit cycles spanning 3-7 years, interest can approach or exceed the penalty amount.
• Double taxation risk: two countries taxing the same income. MAP proceedings take 2-5 years to resolve and resolution is not guaranteed.

A Concrete Example

Consider a mid-size biotech company with $1.5 billion in global revenue, a US parent performing core R&D, and an Irish manufacturing subsidiary with a 6% royalty rate. The IRS determines an arm's length royalty of 14%:

Plus the Irish entity already paid tax on the income attributed to the low royalty. Without MAP relief, the company faces double taxation on $120 million of income. And this is a single audit in a single jurisdiction on a single transaction.

The Compounding Effect

Transfer pricing exposure compounds across multiple transaction types (simultaneous challenges to royalties, R&D pricing, management fees), multiple jurisdictions (a single pricing issue cascading across 5-10 countries), multiple years (3-5 open years per challenge), and secondary adjustments (deemed dividends, constructive distributions). For a mid-size pharma company, aggregate exposure can realistically reach $50 million to $200 million.

Who Should Own Transfer Pricing

• CFO-level sponsorship. Transfer pricing risk belongs on the CFO's dashboard alongside FX risk, credit risk, and interest rate risk. Quarterly updates on compliance status, audit activity, and regulatory developments.
• Dedicated tax leadership. A VP of Tax or Tax Director with transfer pricing expertise should own the compliance program.
• Cross-functional coordination. Transfer pricing touches R&D, manufacturing, commercial, legal, treasury, and finance. A steering committee ensures decisions are informed by operational reality.
• External advisors. Even companies with strong in-house teams benefit from specialized transfer pricing advisors for documentation, benchmarking, DEMPE analysis, APA negotiations, and audit defense.

2 The Pharma Transfer Pricing Landscape

The Six Core Intercompany Transaction Types

1. IP Licensing and Royalties

The entity that owns pharmaceutical IP licenses it to related entities. The royalty rate determines how profits are split between the IP-owning entity and operating entities. This is the single most significant transfer pricing issue in pharma. Typical rates range from 2-5% (pre-clinical compounds) to 15-25% (blockbuster drugs with strong patent protection).

Key risks: Rates set without reference to comparables or economic analysis. Royalties paid to IP holding companies with no DEMPE substance. "Perpetual" licenses at fixed rates that do not account for patent expiry.

2. Contract R&D Services

One entity performs research and development on behalf of another, typically priced at cost-plus (5-15%). The critical distinction: "contract R&D" (routine service, cost-plus) vs. "entrepreneurial R&D" (value-creating, entitled to IP returns). The characterization determines whether the entity earns cost + 8-12% or a share of residual profits.

3. Cost Sharing Agreements (CSAs)

Multiple entities share R&D costs and risks in proportion to expected benefits. Popular in pharma but among the most scrutinized arrangements. The IRS has challenged numerous pharma CSAs, and landmark cases have shaped the rules around buy-in payments and cost pool completeness. Following Altera, stock-based compensation must be included in the cost pool.

4. Contract Manufacturing

Related entity manufactures pharmaceutical products. Compensation ranges from cost plus 5-8% (routine toll manufacturing) to cost plus 12-20%+ (specialized biologics/sterile manufacturing). Tax authorities in the manufacturing jurisdiction challenge whether the entity is being appropriately compensated.

5. Management and Shared Services Fees

HQ charges subsidiaries for corporate services. Among the most frequently challenged intercompany charges. Must demonstrate actual benefit to the receiving entity, exclude shareholder costs, and use allocation keys reflecting actual benefit. India, Brazil, and China are particularly aggressive in disallowing management fees.

6. Distribution and Marketing

Related entities distribute and market pharmaceutical products. Margins range from 2-5% (limited-risk distributor) to 8-15%+ (full-risk distributor with significant marketing, medical affairs, and market access functions). Tax authorities challenge characterization when the entity performs functions beyond simple distribution.

Typical Pharma Multinational Structure

What Triggers a Transfer Pricing Audit

Primary Audit Triggers

1. Significant intercompany transactions without adequate documentation. Missing documentation not only triggers audits but also exposes you to documentation-specific penalties.
2. Profit concentrations in low-tax jurisdictions. CbCR data showing an Irish entity with 100 employees reporting more profit than a US entity with 2,000 employees.
3. Inconsistent transfer pricing positions across jurisdictions. Tax authorities share information through CbCR exchange, joint audits, and the EU Joint Transfer Pricing Forum.
4. Large royalty payments with weak economic substance. Post-BEPS, tax authorities treat royalties to entities without DEMPE substance as presumptive profit-shifting.
5. Operating expense patterns inconsistent with reported functions. A "contract R&D" entity with $50M in personnel costs charged at cost + 10% while its scientists hold decision-making authority.
6. CbCR data showing misalignment between profits and economic activity. High profit/employee ratios, high profits with low tangible assets, significant related-party revenue.

Self-Assessment: Your Audit Risk Profile

If you have three or more "High Risk" answers, engaging a transfer pricing advisor for an immediate risk assessment should be a top priority.

3 The Five Transfer Pricing Methods

Choosing the Right Approach

The OECD prescribes five approved methods for determining arm's length transfer prices. Understanding them is essential because your transfer pricing advisor will apply one or more to each transaction, tax authorities will evaluate whether the method is appropriate, and method selection is itself an audit issue.

Method 1: Comparable Uncontrolled Price (CUP)

Compares the price charged in a controlled transaction to the price in a comparable uncontrolled transaction. The OECD considers CUP the most reliable method when quality comparables exist. However, in pharma, this is the exception — most pharmaceutical IP is unique.

Pharma example: Your US parent licenses an oncology patent to Ireland at 12% royalty. You identify three comparable third-party pharma licensing deals at 11-14%. Your rate falls within the arm's length range.

When it works: Quality comparable transactions exist with similar terms and economics.

When it doesn't: Most pharma IP transactions (unique compounds, confidential terms, first-in-class drugs).

Method 2: Resale Price Method (RPM)

Starts with the resale price to an independent customer, subtracts an appropriate gross margin for the distributor. Declining in usage compared to TNMM.

Pharma example: Singapore buys product at $X, resells at $100. Comparable independent pharma distributors earn 20-28% gross margin. Transfer price should be $72-$80.

Method 3: Cost Plus Method (C+)

Starts with costs, adds an appropriate markup. The workhorse method for contract manufacturing and contract R&D in pharma.

Pharma example: German R&D center total costs: $40M. Comparable CROs charge cost plus 8-14%. Arm's length price: $43.2M-$45.6M.

Method 4: Transactional Net Margin Method (TNMM/CPM)

Compares the net profit margin of the "tested party" to comparable independent companies. The most widely used method in pharma, accounting for 60%+ of transfer pricing studies. Works because comparable company data is broadly available through commercial databases.

Pharma example: Irish manufacturing sub earns 8.3% operating margin. Comparable independent pharma manufacturers' IQR: 6.7%-9.6%. Position within range supports arm's length pricing.

Method 5: Profit Split Method

Allocates combined profit based on each party's relative contribution. Used when both parties contribute unique, valuable intangibles. Two variants: Residual Profit Split (most common in pharma) allocates routine returns first, then splits residual profit; Contribution Profit Split allocates based on overall contribution.

Pharma example: US parent and German R&D center jointly develop a biologic. Combined profit: $350M. After routine returns ($72M to manufacturing and distribution), residual $278M split based on DEMPE contributions: US 60% ($166.8M), Germany 35% ($97.3M), Other 5%.

Which Methods Pharma Actually Uses

Method Selection Decision Tree

4 DEMPE Analysis — The Framework That Changed Everything

Why DEMPE Matters More in Pharma Than Anywhere Else

If there is a single concept that every pharma CFO needs to understand about transfer pricing, it is DEMPE. Since 2015, the OECD requires that profits from intangible assets be allocated based on which entity actually performs the functions of Development, Enhancement, Maintenance, Protection, and Exploitation. Legal ownership alone, without corresponding DEMPE substance, no longer justifies receiving the returns from IP.

This matters more in pharma than virtually any other industry because: a single drug patent can be worth billions; development spans 10-15 years across multiple entities; historical structures created enormous misalignment between IP ownership and DEMPE substance; and the consequences of getting DEMPE wrong are enormous.

The Five DEMPE Functions Explained for Pharma

DEMPE Summary by Entity Type

Common DEMPE Mistakes in Pharma

1. IP holding company with no DEMPE employees. An entity with no scientists, no regulatory professionals, no patent attorneys, and no commercial staff receiving hundreds of millions in royalties.
2. Misallocating Development credit to the funder rather than the entity performing the key scientific and strategic work.
3. Ignoring Enhancement and Maintenance — ongoing value creation and preservation activities that justify continuing shares of IP returns.
4. No documentation of Protection activities. Patent strategy and litigation directed by US legal team, but Protection credit given to the entity in whose name patents are registered.
5. Exploitation profits misaligned with commercial functions. Distribution entities investing heavily in market access and medical affairs but receiving only routine margins.

DEMPE Self-Assessment Tool

5 Documentation Requirements — Master File, Local File, CbCR

The Three-Tier Documentation System

The OECD BEPS Action 13 established a standardized system adopted by most major jurisdictions. Documentation is not optional, quality directly affects penalty exposure, documentation is increasingly shared between jurisdictions, and the cost ($200K-$500K/year) is a fraction of non-compliance cost ($10M-$50M+).

Master File Checklist (12 Items)

1. Organizational structure chart
2. Description of business operations
3. Intangible assets inventory
4. IP ownership and DEMPE mapping
5. Intercompany financial activities
6. Transfer pricing policies
7. Cost sharing arrangements
8. Financial and tax positions
9. Supply chain description
10. Major restructuring history
11. APAs and rulings
12. Financial statements

Local File Checklist (10 Items)

1. Entity functional analysis (functions, assets, risks)
2. Description of each IC transaction
3. Transfer pricing method selection rationale
4. Comparability analysis
5. Benchmarking study results
6. IC agreements (executed copies)
7. Financial data supporting positions
8. Industry analysis
9. Entity financial statements
10. Prior year adjustments (if any)

CbCR Data Points (Per Jurisdiction)

1. Revenue — related party
2. Revenue — unrelated party
3. Profit (loss) before income tax
4. Income tax paid (cash basis)
5. Income tax accrued — current year
6. Stated capital
7. Accumulated earnings
8. Number of employees (FTE)

Key Thresholds by Jurisdiction

6 Pillar Two and the Global Minimum Tax (2024-2026 Update)

The Largest Change to International Tax in a Generation

Pillar Two establishes a global minimum effective tax rate (ETR) of 15% for MNE groups with consolidated revenue of EUR 750 million or more. If any jurisdiction's ETR falls below 15%, a "top-up tax" is applied through one of three mechanisms: QDMTT (jurisdiction itself imposes top-up), IIR (parent jurisdiction imposes), or UTPR (backstop mechanism).

Effective Dates

• January 1, 2024: IIR effective in EU, UK, Japan, South Korea, Canada, Australia.
• January 1, 2025: UTPR effective. Additional countries implementing IIR.
• January 1, 2026: US Side-by-Side (SbS) system effective. QDMTTs enacted in Ireland, Switzerland, Singapore.

How Pillar Two Affects Transfer Pricing

Transfer Pricing Determines Jurisdictional Profit Allocation

Your transfer pricing policies determine where profits are reported, which determines ETR by jurisdiction, which determines top-up tax. Transfer pricing now serves a dual purpose: arm's length compliance AND ETR management.

The Diminished Value of Low-Tax IP Structures

• A 0% tax jurisdiction now has a 15% effective minimum — the tax benefit is eliminated.
• Low-tax patent boxes (5-10% ETR) provide smaller marginal benefit.
• The SBIE rewards genuine substance over shell structures.

The Side-by-Side (SbS) System (January 2026)

• US-parented MNEs: generally exempted from GloBE IIR/UTPR. GILTI serves as the US equivalent. However, QDMTTs in Ireland, Switzerland, Singapore still apply.
• Non-US MNEs: full Pillar Two GloBE rules apply in parent jurisdiction.

Practical Impact on Common Pharma Structures

Irish Manufacturing with Patent Box

Pre-Pillar Two: ~8% ETR with KDB. Post-Pillar Two: 15% minimum via QDMTT. The tax benefit of allocating profit to Ireland is reduced from a 13pp differential to just 6pp.

Singapore Distribution Hub

Pre-Pillar Two: ~6% ETR with DEI. Post-Pillar Two: 15% minimum via QDMTT. The SBIE carve-out rewards entities with significant payroll and tangible assets.

Swiss Principal Company

Pre-Pillar Two: ~10% ETR with cantonal incentives. Post-Pillar Two: Swiss QDMTT brings rate to 15%. The key question remains whether the Swiss entity has sufficient DEMPE substance to justify its profit allocation.

Substance-Based Income Exclusion (SBIE)

The SBIE excludes a portion of GloBE income from top-up tax based on payroll and tangible assets, directly rewarding genuine economic substance.

US Tax Rule Interactions

7 Common Mistakes and How to Avoid Them

Ten Transfer Pricing Pitfalls That Cost Pharma Companies Millions

These ten mistakes are not independent — they often occur together. A company with no documentation typically also has no executed agreements, stale benchmarking, and no DEMPE analysis. Companies that invest in structured compliance avoid most of these pitfalls.

8 Penalties Quick Reference

Penalty Reference: Nine Major Jurisdictions

Penalty Exposure Calculator

The Bottom Line on Penalties

In virtually every major jurisdiction, the penalty for getting transfer pricing wrong exceeds the cost of getting professional help to get it right.

The annual cost of compliance is 0.2% to 3.2% of the potential single-jurisdiction exposure. Transfer pricing compliance is insurance against catastrophic financial risk.

9 Your Transfer Pricing Action Checklist

Immediate Actions (This Quarter)

• Inventory all intercompany transactions by type and value. Create a complete list: IP licenses, contract R&D, cost-sharing, manufacturing, management fees, distribution, loans, guarantees. Use the IC Transaction Log tab in the Transfer Pricing Workbook.
• Identify which entities own intangible assets (legal ownership vs. economic ownership). Flag gaps between legal ownership and DEMPE substance as high-risk.
• Review existing intercompany agreements. Are they signed, dated before transactions began, and reflecting current scope, pricing, and terms?
• Check contemporaneous documentation status. Does a Local File exist for current and prior year? Is it contemporaneous? Does it include functional analysis, benchmarking, and method selection?
• Determine CbCR threshold status (EUR 750M+ consolidated revenue). If close to threshold, monitor growth trajectory.
• Identify your top 3 transfer pricing risk areas. Common: IP royalty rates, IP structures without DEMPE substance, CSAs with undervalued buy-ins, management fees without documentation.

Near-Term Actions (Next 6 Months)

• Engage qualified transfer pricing advisor for documentation review — completeness, benchmarking currency, DEMPE adequacy, cross-jurisdiction consistency.
• Perform or update DEMPE functional analysis for key intangibles through detailed interviews with R&D leaders, patent counsel, regulatory affairs, commercial leadership.
• Update benchmarking studies — refresh financial data annually, new comparable search every 3 years.
• Assess Pillar Two exposure. Model ETR by jurisdiction; identify top-up tax exposure; evaluate SbS/GILTI/FDII/BEAT interactions.
• Review management fee documentation for substance: service catalogs, time records, deliverables, benefit test, shareholder cost exclusion.
• Evaluate APA opportunities for highest-risk transactions (IP royalties, CSA buy-ins, complex manufacturing).

Ongoing Actions (Annual Cycle)

• Update Master File and Local Files annually
• File CbCR within 12 months of fiscal year end (if applicable)
• Refresh benchmarking comparables
• Review and update intercompany agreements for structural changes
• Monitor regulatory changes in key jurisdictions
• Coordinate transfer pricing with indirect tax (VAT/customs)
• Conduct annual transfer pricing risk assessment
• Review Pillar Two safe harbour eligibility
• Maintain intercompany agreement register
• Train functional leaders on TP documentation requirements
• Archive supporting documentation systematically (retain for statute of limitations period)

Annual Documentation Calendar

10 How the Transfer Pricing Workbook Helps

From Guide to Action: A Structured Framework

This guide has covered the essential concepts, methods, and requirements. The critical next step is organizing your company's transfer pricing data in a structured format that supports compliance, reduces advisory costs, and provides audit readiness. That is the purpose of the Transfer Pricing Workbook.

What the Workbook Provides

Entity Register Tab

Maps to: Master File organizational structure, functional analysis. Captures each legal entity with fields for jurisdiction, principal activities, key personnel, functions performed, assets employed, risks assumed, and intercompany relationships.

IC Transaction Log Tab

Maps to: Local File transaction inventory. Records every material intercompany transaction with type, annual value, pricing mechanism, TP method, agreement reference, benchmarking status, and risk flags. Supports global consistency checks.

DEMPE Analysis Tab

Maps to: Master File IP ownership, Local File functional analysis. Maps each intangible asset to entities performing DEMPE functions with percentage contributions. Makes misalignments between legal ownership and DEMPE substance immediately visible.

Benchmarking Tab

Maps to: Local File comparability analysis. Framework for recording comparable company data, IQR calculations, tested party positioning, and pass/fail assessment. Monitor margins against benchmarks throughout the year.

Interactive Dashboard

Maps to: Risk monitoring, compliance tracking. Visualizes intercompany flows, DEMPE allocations, benchmarking status, documentation completeness, and compliance calendar. CFO-level view of compliance across the group.

How It Fits Into Your Compliance Program

Without the workbook: Your advisor spends weeks gathering data from different departments, reconciling inconsistent spreadsheets, and building the framework from scratch. You pay for data collection at advisory rates.

With the workbook: Your team maintains structured data throughout the year. Your advisor begins with organized, consistent data and focuses on value-added analysis. You save advisory hours and get better documentation.

"Think of the workbook as your transfer pricing filing cabinet — organized, structured, and ready for your tax advisor to review. It does not replace professional advice, but it gives your advisors a clean starting point and saves them (and you) billable hours."

What the Workbook Does Not Do

• Provide transfer pricing advice. The workbook captures data; it does not analyze it.
• Replace benchmarking studies. Benchmarking must be prepared using professional databases (Bureau van Dijk Orbis, S&P Capital IQ).
• Substitute for legal agreements. IC agreements must be drafted by qualified counsel.
• File tax returns or CbCR reports.
• Guarantee audit outcomes. The workbook increases the probability of favorable outcomes by ensuring organized, comprehensive documentation.

Frequently Asked Questions

How much should my company spend on transfer pricing compliance?

For a mid-size pharma ($500M-$5B revenue, 5-15 countries): $200,000-$500,000 annually in advisory fees, plus internal staff time. Companies with complex IP structures may spend $500K-$1M+. Compare to potential exposure of $10M-$100M+. Spending 0.5-1.0% of intercompany transaction volume on compliance is a reasonable benchmark.

How often should we update documentation?

Master Files and Local Files: annually. Benchmarking financial data: annually. Comparable search: every 3 years. DEMPE analyses: whenever material changes occur. CbCR: annually.

What is the biggest transfer pricing risk for pharma right now?

DEMPE misalignment remains the single largest risk. Companies with IP legally owned by entities lacking DEMPE substance face the most significant audit exposure. The second-largest risk is inadequate documentation.

Should we get an APA?

APAs are worth considering if you have high-value IC transactions (>$50M annually), inherently subjective transactions (IP royalties, CSA buy-ins), or a history of disputes. Bilateral APAs are preferred because they eliminate double taxation risk. Investment of $500K-$2M over 2-3 years is justified when potential exposure exceeds $10M.

We are a pre-revenue biotech. Do we need TP documentation?

Yes. Common pre-revenue IC transactions include contract R&D services, CSA payments, management fees, and intercompany loans. Establishing proper documentation from the beginning is significantly less expensive than retroactive compliance.

How do digital health and AI-driven drug discovery affect transfer pricing?

AI/ML algorithms, real-world evidence databases, and digital health platforms are intangible assets subject to DEMPE analysis. Intercompany data transfers, algorithm licensing, and platform access fees are all transfer pricing transactions requiring arm's length pricing. Ensure your TP advisor has experience with technology-related transactions.

What is the difference between GILTI and Pillar Two?

GILTI is US-only, blended worldwide, with a ~10.5% effective rate and QBAI substance carve-out. Pillar Two applies to all MNEs with EUR 750M+ revenue, calculated per-jurisdiction at 15%, with SBIE substance carve-out. For US-parented pharma, both regimes apply and must be modeled together.

Glossary of Key Terms